Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176), has reported a staggering year-on-year (YOY) increase of 103,397.96% in its 2024H1 financial report, with revenues reaching RMB 80.4934 million. The second quarter of the year saw even more impressive growth, achieving RMB 56.1739 million, which represents a 130.98% month-on-month increase. This robust performance is primarily attributed to the company’s sales of generic versions of pzopanib and nratinib, which commenced in the fourth quarter of 2023.
Despite the significant revenue growth, Asieris Pharma reported a net loss of RMB 183.9 million for the period, which is a slight improvement compared to the same period last year when the net loss was RMB 185.4 million.
The company boasts a robust pipeline with 13 products and 18 investigational programs. One of its key products, APL-1702, is a groundbreaking cold light photodynamic drug-device combination for the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix. As it awaits regulatory approval in China, Asieris Pharma has established a women’s health business department in 2024 to prepare for the product’s commercialization. Additionally, Hexvix (APL-1706), the only globally approved agent for assisting in the diagnosis or surgery of bladder cancer, is also pending regulatory decisions in China.- Flcube.com
